Management of CKD in T2D – where are we today?
Chairs: Paola Fioretto (ITA), Jose Luis Górriz (ESP) 19:45 – 19:46 Introduction Paola Fioretto (ITA) 19:46 – 19:48 Global burden of CKD and T2D Jose
INDUSTRY
Menu
Chairs: Paola Fioretto (ITA), Jose Luis Górriz (ESP) 19:45 – 19:46 Introduction Paola Fioretto (ITA) 19:46 – 19:48 Global burden of CKD and T2D Jose
Chairs: Irene Bretón (ESP), Helena Cortez-Pinto (PRT) 18:45 – 18:47 Introduction Irene Bretón (ESP)Helena Cortez-Pinto (PRT) 18:47 – 18:57 MASH as a metabolic disease Irene
Chair: Ania Jastreboff (USA) 18:45 – 18:52 Welcome Ania Jastreboff (USA) 18:52 – 19:02 Why should obesity be treated as a serious chronic disease? Arya
Chair: Harpreet S. Bajaj (CAN) 12:15 – 12:22 Welcome and introduction Harpreet S. Bajaj (CAN) 12:22 – 12:30 Navigating T2D treatment: combining once-weekly insulins and
Chair: Sue Pedersen (CAN) 18:30 – 18:45 Welcome and introductions: Connecting the dots between cardiovascular, kidney and metabolic diseases Sue Pedersen (CAN) 18:45 – 19:35
Chair: Esteban Jodar (ESP) 09:00 – 09:10 Welcome and introduction Esteban Jodar (ESP) 09:10 – 09:30 Basal insulin treatment in people with T2D: where is
